No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.

Hereditary Cancer Info > Cancer Treatment > PARP Inhibitor Therapy

Toggle Menu

PARP Inhibitor Therapy

There are many options for treating hereditary cancers. Choice of treatment can be personalized based on cancer type, stage and genetics.

Related Force Information

Be Empowered Webinar: BROCADE3 Study
Dr. Shannon Puhalla, Director, Breast Cancer Clinical Research Program, University of Pittsburgh Cancer Institute discusses the BROCADE 3 Study. Brocade3 is a research study evaluating the safety and effectiveness of an investigational medication in addition to treatment with chemotherapy for patients with metastatic or locally advanced BRCA associated, HER2-negative breast cancer

Be Empowered Webinar: OlympiA Trial
Dr. Charles E. Geyer, Professor of Medicine and Harrigan, Haw, Luck Families Chair in Cancer Research at the Virginia Commonwealth University, Massey Cancer Center describes the OlympiA trial. OlympiA is the first clinical trial for people with a BRCA1 or BRCA2 mutation who have been recently diagnosed with stage 2 or stage 3 breast cancer. The study will evaluate whether the PARP inhibitor olaparib is safe and improves outcomes.

PARP Inhibitor Research Update Webinar
2013 webinar presented by Dr. Susan Domchek with updates on research on these agents.

Update: PARP Inhibitor Research
Article from Spring 2013 FORCE Newsletter with information on the status of PARP inhibitor research.

BROCADE Study - A PARP inhibitor study for advanced breast cancer
Article from Spring 2013 FORCE Newsletter with information about the BROCADE Study, a PARP inhibitor clinical trial for people with advanced BRCA-associated breast cancer.

Treatment for Triple-Negative Breast Cancer
2010 FORCE webinar presented by Dr. Melinda Telli of Stanford, providing updates on research specific to triple-negative breast cancer.

Clinical Trials
FORCE page with Information about participating in research and clinical trials including protections for patients who participate.

PARP Inhibitor Research Studies
FORCE listing and links to featured research studies enrolling patients with hereditary cancer.

Metastatic Hereditary Breast Cancer Treatment Research: BROCADE 3 Study
FORCE blog post describing the BROCADE 3 study.

Updates in Research on Treating Hereditary Cancers
FORCE blog post updating current research on using PARP inhibitors to treat hereditary cancers.

Update on Pancreatic Cancer Genetics Research
FORCE blog post describing hereditary cancer genetics and the POLO study.

Other Websites

Information on Lynparza
Website from manufacturers of Lynparza, a PARP inhibitor that is the first targeted therapy approved for treatment of recurrent ovarian cancer in women with a BRCA mutation.

Store My Tumor
StoreMyTumor is a company that offers tumor banking services. You can decide before surgery to preserve your tumor tissue to enable participation in breakthrough, personalized treatments including immunotherapy.

FORCE:Facing Our Risk of Cancer Empowered